Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology will hold a conference call on May 6, 2021, at 1:30 p.m. PDT to discuss its Q1 2021 financial results. Investors can join by dialing 1-877-709-8150 domestically or 1-201-689-8354 internationally. A live webcast and presentation slides will be available on the company's website. Puma focuses on innovative cancer therapies, notably NERLYNX, an FDA-approved treatment for HER2-positive breast cancer, with additional approvals in the U.S. and Europe.
- FDA-approved NERLYNX for HER2-positive breast cancer, enhancing market presence.
- Strong global development rights for innovative cancer treatments.
- None.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 6, 2021, following the release of its first quarter 2021 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005925/en/
FAQ
When is Puma Biotechnology's Q1 2021 financial results conference call?
How can I access the Puma Biotechnology conference call?
What is NERLYNX and its significance for Puma Biotechnology?
What kind of products does Puma Biotechnology develop?
